"Efficacy of Once-weekly GLP 1 Analogue: Semaglutide. A Multicenter Experience From Pakistan."
试验速览
- 阶段
- 早期 1 期
- 入组人数
- 300
- 试验地点
- 2
- 主要终点
- Change in glycemic Index in Diabetes mellitus type-2 Patients
研究概览
简要总结
A prospective interventional trial for 9 months will be carried out on 300 type-2 diabetes mellitus volunteer patients who are above 18-year-old and participants will be selected through consecutive sampling and will be evaluated on the basis of glycemic index and history of patients. Selected parameters will be measured at baseline and after the 12 weeks of therapy. Statistical analysis will be carried out by SPSS, ANOVA, and t-test.
From this experimental design, we are expecting improvement in the management of glycemic index, reduction in systolic and diastolic blood pressure, and reduction in weight GLP-1 naive patients.
详细描述
Patients will be recruited from all the 12 centers included in the trial across Pakistan and data will be electronically transferred to the main center. All GLP-1 naive patients fulfilling the inclusion criteria will be recruited after informed written consent and started on Semaglutide injection 0.25mg for 2 weeks and will be escalated to 0.5 mg for the next 10 weeks. Socio-Demographic Data and health vitals including height, weight, BMI, baseline HbA1c, FBS and RBS will be recorded in preset Performa. All those who agree to participate will be given structured education on diet and exercise and those willing to comply will be recruited. A research assistant will be recruited and trained to teach the injection technique and discuss the adverse effects of Semaglutide to the participants. Patients taking DPP-4 inhibitors will be switched to GLP-1 analogue and only a single drug change in the form of adding Semaglutide will be done at the time. Semaglutide injection technique will be explained to the patient and one injection at a time will be provided to the patient to ensure compliance and avoid bias in the study. Patients will be asked to revisit after 4 weeks with the used injection device. After completion of 3 months of treatment vitals including height, weight, BMI, baseline HbA1c, FBS and RBS will be recorded in preset Performa.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Both male and female Type 2 Diabetic patients with age ≥18 years.
- •Patients with HbA1c ≥ 7.5 % - ≤ 10.0%
- •Patients with BMI ≥ 30
排除标准
- •Patients with Type 1 Diabetes Mellitus
- •Patients with Gestational Diabetes Mellitus.
- •Patients with Chronic Renal Failure with eGFR of ≤ 30ml/min
- •Patient already on another GLP 1 analogue
- •The patient stopped any GLP1 analogue treatment less than 3 months back.
- •Patients with history of chronic pancreatitis or pancreatic cancer.
研究组 & 干预措施
semaglutide
semaglutide is an anti-diabetic medication used for the treatment of type 2 diabetes and long-term weight management. Semaglutide acts like human glucagon-like peptide-1 in that it increases insulin secretion, thereby increasing sugar metabolism
干预措施: Semaglutide Pen Injector (Drug)
结局指标
主要结局
Change in glycemic Index in Diabetes mellitus type-2 Patients
时间窗: 3 months
Once weekly Semaglutide may result to remarkably change HbA1c level with in 3 months of use
次要结局
- Weight Changes in Obese People(3 months)
研究者
NASEER AHMED
Assistant Professor
Aga Khan University